Amgen Inc.

NASDAQ:AMGN

Drug Manufacturers - General

Healthcare
$443.89 -2.03%

-$6.93 today

Market cap
$240.11B
Beta
0.42
P/E (TTM)
23.2
EPS (TTM)
$14.44
Dividend yield
2.93%
52W Low $267.83High $391.29

Volume 2.58M

Average 2.76M

AMGN Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Amgen Inc.NASDAQ: AMGN

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity rises 57.4% from a year ago

Total equity stood at $11.69B at the end of Q2 FY2026, up 57.4% from a year earlier and up 27.2% from the prior quarter. Over 3 fiscal years it compounded at +33.2% a year.

Context

  • Total equity amounted to 12.2% of total assets at the end of Q2 FY2026, up 3.8 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +57.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$11.69B+27.2% QoQ
Last fiscal yearDec 2025
$8.66B+47.3% YoY
Year agoJun 2025
$7.43B+57.4% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+57.4%——
1 year+47.3%——
3-year CAGR+33.2%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
8.66B USD
Year-over-year change
+47.3%
4-year CAGR
+6.6%

Total Equity vs competitors

How AMGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +57.4% is the 2nd highest of 10, against a peer median of -0.3%.
  • Total equity amounts to 12.2% of total assets for AMGN, versus a peer median of 32.3%.
AMGN Competitors
Total Equity for AMGN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PFEPfizer Inc.Jun 2026$85.49B USD-4.0%-3.3%42.5%
JNJJohnson & JohnsonSep 2026$81.53B USD+2.8%+2.0%41.3%
AZNAstraZeneca PLCSep 2026$51.72B USD+12.5%+9.5%43.2%
MRKMerck & Co., Inc.Jun 2026$41.98B USD-14.4%+4.6%32.3%
NVSNovartis AGJun 2026$41.95B USD-0.3%-7.8%34.4%
LLYEli Lilly and CompanyJun 2026$33.88B USD+84.6%+35.0%23.8%
BMYBristol-Myers Squibb CompanyJun 2026$22.32B USD+27.6%-15.9%25.5%
GSKGSK plcJun 2026£17.07B GBP-13.2%+16.4%27.8%
AMGNAmgen Inc.Jun 2026$11.69B USD+57.4%+33.2%12.2%
ABBVAbbVie Inc.Jun 2026-$5.89B USD-4166.7%—4.4%
Peer median (excluding AMGN) —-0.3%+3.3%32.3%

Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents7.99B7.63B10.94B11.97B9.13B
Short-term Investments48M1.68B000
Net Receivables5.84B6.39B7.94B7.5B9.57B
Inventory4.09B4.93B9.52B7B6.23B
Other Current Assets200M355M281M419M4.13B
Total Current Assets19.39B22.19B30.33B29.03B29.06B
Property, Plant & Equipment (Net)5.18B5.43B5.94B6.54B8.52B
Goodwill14.89B15.53B18.63B18.64B18.68B
Intangible Assets15.18B16.08B32.64B27.7B22.28B
Long-term Investments004.71B5.36B6.8B
Tax Assets00000
Other Non-current Assets6.52B5.9B4.9B4.58B5.25B
Total Non-current Assets41.78B42.94B66.82B62.81B61.53B
Total Assets61.17B65.12B97.15B91.84B90.59B
Account Payables1.37B1.57B1.59B1.91B2.37B
Short-term Debt87M1.59B1.44B3.55B4.6B
Tax Payables701M1.2B1.66B00
Deferred Revenue00000
Other Current Liabilities1.62B1.1B1.38B1.33B1.44B
Total Current Liabilities12.18B15.69B18.39B23.1B25.49B
Long-term Debt33.22B37.35B63.17B56.55B50.01B
Deferred Tax Liabilities011M2.35B1.62B1.37B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities9.06B8.41B7.01B4.7B5.07B
Total Non-current Liabilities42.28B45.77B72.53B62.86B56.44B
Total Liabilities54.47B61.46B90.92B85.96B81.93B
Common Stock32.1B32.51B33.07B33.53B34.02B
Retained Earnings(24.6B)(28.62B)(26.55B)(27.59B)(25.11B)
Accumulated OCI(796M)(231M)(289M)(66M)(258M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity6.7B3.66B6.23B5.88B8.66B
Total Debt33.31B38.95B64.61B60.1B54.6B
Net Debt25.32B31.32B53.67B48.13B45.48B

Amgen Inc.

NASDAQ:AMGN

Intrinsic Alpha fair value

Locked

Current Price

$443.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.